Madrigal Pharmaceuticals, Inc. MDGL
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a GI/hepatology drug developer. Its lead program, Rezdiffra (resmetirom), is in Phase 3 for noncirrhotic MASH with moderate to advanced liver fibrosis. Its next catalyst on record is resmetirom: MAESTRO-NASH OUTCOMES results (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: resmetirom — MAESTRO-NASH OUTCOMES results (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Rezdiffra | MASH F2-F3 | small molecule | Approved |
| resmetirom | compensated MASH cirrhosis (MAESTRO-NASH OUTCOMES) | small molecule | Phase 3 |
| ervogastat | MASH combination | small molecule | Phase 2 |
| MGL-2086 | MASH/metabolic | unclear | Phase 1 |
| MGL-0795 | siRNA | RNA (siRNA/ASO/mRNA) | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.